Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of June 2025. The document serves as a transaction notification regarding a sale of company securities by a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details a specific securities transaction.
| Transaction Detail | Value |
|---|---|
| Instrument | Ordinary Shares (31½ pence each) |
| Transaction Type | Sale |
| Volume | 77,000 shares |
| Price per Share | £14.9825 |
| Transaction Date | May 30, 2025 |
| Exchange | London Stock Exchange (XLON) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document records a single insider transaction and does not compare performance against prior periods.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a regulatory disclosure of an insider trade.
Key Facts for Investor Verification
- Insider Identity: James Ford, SVP and Group General Counsel, Legal and Compliance.
- Transaction Nature: Initial notification of a sale of 77,000 ordinary shares.
- Transaction Value: Approximately £1,153,652.50 (77,000 shares × £14.9825).
- Timing: The trade occurred on May 30, 2025, and was reported on June 2, 2025.